This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Opstal, J. M. Articles by Vos, M. A. Search for Related Content PubMed PubMed Citation Articles by van Opstal, J. M. Articles by Vos, M. A. Related Collections Electrophysiology Cardiovascular Pharmacology Animal models of human disease Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2001;104:2722.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Chronic Amiodarone Evokes No Torsade de Pointes Arrhythmias Despite QT Lengthening in an Animal Model of Acquired Long-QT Syndrome

Jurren M. van Opstal, MD; Marieke Schoenmakers, MD; S. Cora Verduyn, PhD; S.H. Marieke de Groot, MD, PhD; Jet D.M. Leunissen; Ferenc F. van der Hulst, BSc; Mirella M.C. Molenschot, MD; Hein J.J. Wellens, MD, PhD; Marc A. Vos, PhD

From the Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands.

Correspondence to Marc A. Vos, PhD, Department of Cardiology, Academic Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, the Netherlands. E-mail m.vos{at}cardio.azm.nl

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Amiodarone is an effective antiarrhythmic drug rarely associated with torsade de pointes arrhythmias (TdP). The noniodinated compound dronedarone could resemble amiodarone and be devoid of the adverse effects. In the dog with chronic complete atrioventricular (AV) block (CAVB) and acquired long-QT syndrome, the electrophysiological and proarrhythmic properties of the drugs were compared after 4 weeks of oral treatment.

Methods and Results— Amiodarone (n=7, 40 mg · kg^-1 · d^-1) and dronedarone (n=8, 20 mg/kg BID) were started at 6 weeks of CAVB (baseline). Six dogs served as controls. Surface ECGs and endocardially placed monophasic action potential catheters in the left (LV) and right (RV) ventricles were recorded to assess QTc time, action potential duration (APD), interventricular dispersion (APD=LV APD minus RV APD), early afterdepolarizations (EADs), ectopic beats, and TdP. Both amiodarone (+21%) and dronedarone (+31%) increased QTc time. Amiodarone showed no increase in APD in 4 of 7 dogs, whereas dronedarone augmented APD in 7 of 8 animals. After dronedarone, TdP occurred in 4 of 8 dogs with the highest APD (105±20 ms). TdP was never seen with amiodarone, not even in the dogs that had APD values comparable to those with dronedarone. Furthermore, a difference existed in EADs and ectopic activity incidence (dronedarone 3 of 8; amiodarone 0 of 7), which was also seen during an epinephrine challenge.

Conclusions— In the CAVB dog model, both amiodarone and dronedarone prolong QT time (class III effect). The absence of TdP with amiodarone seems to be related to homogeneous APD lengthening in the majority of dogs and the lack of EADs and/or ventricular ectopic beats in all.

Key Words: antiarrhythmia agents • electrophysiology • hypertrophy • action potentials

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Amiodarone is the most potent antiarrhythmic drug in the prevention of life-threatening ventricular arrhythmias and demonstrates a very low incidence of torsade de pointes arrhythmias (TdP).^1–4 The noncardiac adverse effects of amiodarone, however, attributed to the iodinated nature of the molecule, limit its clinical applicability.^5,6 The noniodinated benzofuran derivative dronedarone, which is structurally related to amiodarone, could possess similar antiarrhythmic efficacy as well as the low proarrhythmic potential of amiodarone and be devoid of the unwanted side effects.^7–9

The anesthetized dog with chronic complete atrioventricular (AV) block (CAVB) and acquired long-QT syndrome is a suitable model to assess the proarrhythmic potential of intravenously administered antiarrhythmic drugs and to study factors involved in acquired TdP.^10–15 TdP in this model depends on (1) bradycardia, (2) long repolarization times, (3) large regional dispersion of repolarization, and/or (4) afterdepolarizations and triggered ectopic activity.^10,15 The aim of the present study was to determine and compare the electrophysiological changes and possible proarrhythmic consequences of chronic oral administration of amiodarone and dronedarone in this animal model.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
General
Twenty-seven mongrel dogs (weight 26±5 kg, 18 female) were subjected to an initial experiment for creation of CAVB and implantation of an epicardial pacing electrode. The procedure, anesthesia, ventilation, and preoperative and postoperative care have been described in previous articles from our group.^10,11,15 The actual study started at 6 weeks of CAVB, because the heart had then reached a stable state in the different ventricular remodeling processes.¹⁴

Animal handling was in accordance with the European Directive for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes (European Union Directive No. 86/609/CEE).

Studies in Anesthetized Dogs at 6 and 10 Weeks of CAVB
Figure 1 provides a flow chart of the experiment performed at 6 and 10 weeks of CAVB, consisting of electrophysiological and hemodynamic recordings at baseline and during proarrhythmic challenges.

View larger version (24K): [in this window] [in a new window]   Figure 1. Flow chart of experiment at 6 and 10 weeks of CAVB. T=0 indicates start of anesthesia; EB, ectopic beats; CEB, consecutive ectopic beats; and EP, electrophysiology.

A 6-lead surface ECG, 2 endocardial monophasic action potentials (MAPs, EP Technologies Inc) in the left (LV) and right (RV) ventricles, and an LV pressure signal (Sentron Europe Inc) were simultaneously registered and stored. For definitions, amplifications, and filter settings, we refer to previous publications.^10,11,15

Two intervention protocols were performed to evoke arrhythmias: (1) short-long-short pacing from the RV MAP (4 · 600 ms+1200 ms+extrastimulus¹⁰) and (2) IV administration of epinephrine (1 µg · kg^-1 · min^-1) for 20 minutes (Figure 1). Six dogs were excluded from the study before the start of amiodarone or dronedarone because of clinical signs of heart failure in 1 animal and inducible TdP by pacing in 5 animals. The latter is associated with sudden cardiac death in this model, disallowing screening for proarrhythmic potential of class III drugs.¹⁶

The 21 remaining animals were randomized to (1) the control group (n=6), (2) amiodarone (n=7, 40 mg · kg^-1 · d^-1), and (3) dronedarone (n=8, 20 mg/kg BID). Drugs were provided by Sanofi-Synthélabo, Montpellier, France, and administered at fixed times. Dosages were chosen on the basis of previous publications.^8,9,12,17 After 4 weeks of oral administration, the studies were repeated (CAVB 10 weeks) and the dogs euthanized. Heart, lungs, and liver were excised to determine the ratios of organ weight to body weight (BW).

Studies in Conscious Dogs Between 6 and 10 Weeks of CAVB
Both during idioventricular rhythm (IVR) and at a paced cycle length (CL) of 1000 ms (pacing from the LV epicardial electrode), the QT time and ventricular effective refractory period (VERP) were assessed every week. VERP was determined at twice diastolic threshold by delivering an extrastimulus at incremental steps of 5 ms.

Data Analysis and Definitions
Figure 1 shows the time periods of the electrophysiological and functional measurements and arrhythmia scoring.

The following parameters were measured offline: LV end-systolic pressure, LV end-diastolic pressure, LV peak rate of pressure rise (+dP/dt_max), CL-IVR, QT time, and duration of the LV and RV MAP (MAPD) at 100% repolarization. QTc time was calculated by the Van de Water formula.¹⁸ Furthermore, the planimetric area of the JT wave (_J^T, mV · ms) in lead II of the surface ECG was assessed as a noninvasive parameter of dispersion of repolarization.

All data presented are the mean of 5 consecutive beats during stable CL-IVR after 1 hour of anesthesia. Interventricular dispersion (MAPD) was calculated as LV MAPD minus RV MAPD. Early afterdepolarizations (EADs) were assessed on the MAP signals. Spontaneously occurring ventricular ectopic beats were counted (1) before catheter introduction during a 5-minute time interval and (2) during the last 5 minutes of the 20-minute epinephrine infusion period. An ectopic beat was defined as a ventricular complex having a coupling interval of <50% CL-IVR. Arrhythmic activity was scored on the basis of (1) single ectopic beats, (2) consecutive ectopic beats, (3) monomorphic nonsustained ventricular tachycardia (MVT, >5 consecutive ectopic beats), or (4) TdP.

Determination of Drug Levels
Venous blood samples were taken weekly. Myocardial tissue samples (1 cm³) were obtained from the free wall of both ventricles at death. Analyses of drug plasma and tissue levels, including metabolites (n-monodebutyldronedarone and n-desethylamiodarone) were performed by the Department of Pharmacokinetics, Sanofi-Synthélabo, Montpellier, France. For details concerning analyses, see Reference 9.

Statistics
Pooled data are expressed as mean±SD except for the arrhythmia scoring data during epinephrine administration, which are expressed as mean±SEM. Serial comparisons were performed by paired Student’s t test and single parameters between independent groups by 2-way ANOVA with a post hoc Bonferroni t test. Statistical analysis of the time-dependency studies was done by ANOVA for repeated measures. Incidence was compared by ² testing. Values of P<0.05 were considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Electrophysiological Studies in Conscious Dogs Between 6 and 10 Weeks of CAVB
All 21 animals survived the 4 weeks of drug administration. In 1 dog of the amiodarone-treated and 2 dogs of the dronedarone-treated groups, the VERP determinations could not be completed because of electrode dysfunction.

In the control group, the CL-IVR and QT times remained similar (CL-IVR 1245±150 ms and QT time 315±15 ms at 6 weeks CAVB versus 1270±185 and 320±25 ms at 10 weeks CAVB).

Both amiodarone (1230±185 to 1675±435 ms) and dronedarone (1145±165 to 1360±190 ms) had a significant bradycardic effect. QT time prolonged significantly for both drugs at IVR (amiodarone 290±15 to 355±26 ms and dronedarone from 295±25 to 365±30 ms). Also at 1000-ms paced CL, QT time (amiodarone +12% and dronedarone +13%) as well as VERP (amiodarone 191±13 to 223±18 ms and dronedarone 204±30 to 243±33 ms) increased (Figure 2).

View larger version (17K): [in this window] [in a new window]   Figure 2. Temporal behavior of QT time (top) and VERP (bottom) during amiodarone (left) and dronedarone (right) treatment in conscious dogs at paced CL of 1000 ms. x axis, time in weeks after CAVB. Start of treatment at 6 weeks CAVB. Both drugs increased QT time and VERP similarly ($P<0.05 vs 6 weeks CAVB).

Studies in Anesthetized Dogs at 6 and 10 Weeks of CAVB
The baseline electrophysiological values were comparable between the 3 groups (Table, left). EADs, ectopic activity, and TdPs were absent. The hemodynamic parameters were also similar, although the amiodarone group had a relatively low LV end-diastolic pressure value. These electrophysiological and hemodynamic data are in agreement with data published previously in the CAVB dog.^10,11,15 Epinephrine administration decreased CL-IVR and all repolarization parameters, including MAPD (data not shown). The average number of epinephrine-evoked ectopic beats and MVTs at 6 weeks of CAVB is depicted in Figure 3 (n=21, control 6 weeks).

View this table: [in this window] [in a new window]   Table 1. Electrophysiological and Hemodynamic Results Before and After 4 Weeks of Amiodarone or Dronedarone Treatment Compared With the Control Group

View larger version (24K): [in this window] [in a new window]   Figure 3. Arrhythmia scoring for 5-minute period during epinephrine infusion for 2 control (6 and 10 weeks CAVB), amiodarone-, and dronedarone-treated groups. x axis, division between single ectopic beats (EB), consecutive ectopic beats (CEB), MVT, and TdP. y axis, mean number of different arrhythmias per dog. Dronedarone group demonstrated significantly (*P<0.05) more ectopic activity.

The right side of theTable presents the electrophysiological and hemodynamic results after 4 weeks of treatment. The QT time and LV and RV MAPD were longer for both drugs compared with the control group. Dronedarone had a stronger "class III effect": eg, dronedarone increased QTc time from 350±50 to 460±30 ms (31%), whereas amiodarone increased QTc time from 330±35 to 400±60 ms (21%, P<0.05 for both). Remarkably, for the amiodarone group, the prolonged QT time was accompanied by an augmented MAPD in only 3 dogs (Figure 4). As a consequence, MAPD did not increase significantly (Table). In contrast, dronedarone affected LV MAPD far more than RV MAPD in 7 of 8 dogs, augmenting MAPD significantly (Figure 4). Also, JT area increased in the dronedarone group (from 157±89 to 200±104 mV · ms), whereas the control and the amiodarone-treated groups remained similar (Table).

View larger version (20K): [in this window] [in a new window]   Figure 4. Individual data of QT time (left) and interventricular dispersion (MAPD, right) are shown before (b) and after amiodarone (amio) or dronedarone (dron) treatment. Left, Amiodarone prolonged QT time in 6 of 7 dogs, but was associated with increase in MAPD (right) in only 3 of 7 (, left). Dronedarone increased QT time in all and MAPD in 7 of 8 dogs (right), being associated with TdP for those dogs having highest MAPD (, right).

Arrhythmias With Amiodarone and Dronedarone
At 10 weeks of CAVB, none of the animals in the control or amiodarone group showed EADs or spontaneous ectopic activity in the 5-minute period before catheter introduction. In contrast, 6 of 8 dronedarone animals showed EADs (P<0.01 versus amiodarone) on the LV MAP, of which 3 also developed considerable ventricular ectopic activity.

In the control group, spontaneous TdP was never seen, but it could be induced by pacing in 1 of 6 animals. In the amiodarone group, no spontaneous or pacing-induced TdP occurred. Multiple episodes of spontaneous TdP (Figure 5) were seen in 3 dogs with dronedarone treatment. Furthermore, TdP was inducible by pacing in 1 animal, in which EADs but no ectopic beats were observed, resulting in a total TdP incidence of 4 of 8 dronedarone-treated dogs. Subgroup analysis looking at LV MAPD resulted in an absence of ectopic beats and spontaneous or inducible TdP for those dogs having an LV MAPD <500 ms.

View larger version (95K): [in this window] [in a new window]   Figure 5. Spontaneously occurring TdP during chronic dronedarone treatment in an anesthetized CAVB dog. Four panels with lead II of surface ECG at 10 mm/s demonstrate several episodes of TdP during 17-minute period. Bottom, Single LV and RV MAPs are shown to exemplify MAPD (520 minus 430 ms).

In the dronedarone-treated group only, epinephrine administration resulted in an increased number of ectopic beats (Figure 3).

Myocardial Tissue and Plasma Concentrations
The plasma levels of dronedarone (1.3±0.3 mg/L), amiodarone (3.5±0.6 mg/L), and their metabolites were in agreement with data published recently.⁹ The myocardial tissue data of amiodarone (LV 17.9±3.8, RV 13.3±3.8 mg/kg), n-desethylamiodarone (LV 12.7±2.9, RV 8.0±2.3 mg/kg), dronedarone (LV 13.5±3.8, RV 13.2±3.9 mg/kg), and n-monodebutyldronedarone (LV 2.8±0.7, RV 3.4±0.9 mg/kg) were comparable to data published by Latini et al¹⁹ and Merot et al.²⁰ The 3 animals showing an increased MAPD on amiodarone also tended to have higher tissue levels of the compound (LV 25.7±11.6 versus 12.0±2.6 mg/kg) and its metabolite (LV 16.7±10.6 versus 9.8±3.4 mg/kg) compared with the other 4 animals.

Autopsy Data
At autopsy, the heart weight/BW (12.4±1.2 g/kg in the control, 13.0±0.9 g/kg in the dronedarone, and 11.6±2.1 g/kg in the amiodarone groups), liver weight/BW (26.7±3.2, 28.1±4.4, and 30.4±2.3 g/kg, respectively), and lung weight/BW (12.6±2.9, 14.5±4.3, and 10.8±2.4 g/kg) ratios were similar in the 3 groups.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the CAVB dog, both amiodarone and dronedarone prolonged QT time and VERP significantly (Figure 2). These increases in QT time and VERP for amiodarone under conscious conditions are comparable to human data.²¹ Amiodarone, unlike dronedarone, evoked no EADs, ectopic beats, or TdP and did not increase dispersion of repolarization significantly. In contrast, other antiarrhythmic drugs administered intravenously in the CAVB dog, like dofetilide or almokalant, augmented dispersion of repolarization and elicited EADs, ectopic beats, and TdPs.^10,15

Amiodarone does not fit well into conventional antiarrhythmic classification schemes. Used long-term, amiodarone prolongs the ventricular APD and therefore is classified generally as a class III agent. However, the drug also possesses class I (sodium channel blockade), class II (anti-adrenergic), and class IV (calcium channel blockade) effects.^5,8,22 The multiple ion channel interaction by amiodarone has been speculated to contribute to its minimal reverse use dependency and low incidence of clinical TdP arrhythmias, even in patients who develop TdP on other antiarrhythmics.^5,22–24 Dronedarone, given either long-term or short-term, has been suggested to possess a similar electrophysiological profile, but the effects of chronic dronedarone on specific cardiac ion channels are still unknown.^7–9

Arrhythmic Parameters: Dispersion
TdP is generally thought to be dependent on 2 interrelated mechanisms: the trigger (ectopic beat) and the substrate (dispersion).^10,25 The length of the LV MAP plays an important role in both, either by creating regional dispersion of repolarization between the ventricles or by generating EAD-dependent triggered arrhythmias.²⁶ Furthermore, EADs will contribute to dispersion when their presence in the ventricles is not homogeneous. Second, when EADs give rise to ectopic beats, electrical heterogeneity will be further augmented (eg, MAPD),²⁷ a concept that has been referred to as modulated dispersion of repolarization.^27–29

Dronedarone increased MAPD in 7 of 8 dogs (Figure 4), based on a more pronounced lengthening of the MAPD in the LV versus the RV. Despite QT lengthening and bradycardia, amiodarone prolonged the ventricular APDs homogeneously in 4 of 7 dogs, resulting in a nonsignificant overall increase of MAPD. Similar results on equal or reduced transmural dispersion during chronic amiodarone treatment have been described by others, both in vivo and in vitro,^17,20,30 although QT time lengthening was not convincingly present in these studies. The divergent response of MAPD in 3 dogs of the amiodarone group could be based on a different distribution or clearance of the drug.

Torsade de Pointes Arrhythmias: The Trigger
In the CAVB dog, drug-induced TdP has been associated with ventricular ectopic activity and a pronounced MAPD.^10,15 Dronedarone resulted in a 50% TdP incidence and was observed in (1) the 3 dogs with multiple ectopic beats (Figure 5) and (2) the 4 dogs with the highest MAPD (Figure 4). Amiodarone did not induce TdP in any of the dogs, not even in those with a similar magnitude of MAPD.

Therefore, the lack of TdP with amiodarone appears to be linked to the prevention of EADs and/or ectopic activity, even during proarrhythmic challenges with pacing protocols and epinephrine administration. Absence of EADs after amiodarone treatment was observed earlier in M cells¹⁷ and in isolated rabbit right ventricular tissue.³¹

Why dronedarone-treated animals respond differently is unclear, but this could be related to (1) unfortunate randomization, (2) the selected dosage, or (3) dissimilar electrophysiological effects. With respect to point 1, the 3 dogs showing TdP after dronedarone had relatively high LV MAPD at baseline (6 weeks CAVB) (mean 405±25 ms) compared with amiodarone (310±25 ms). The length of LV MAPD at baseline was recently described as a predisposing factor for (drug-induced) arrhythmias.¹⁶ Point 2, although the selected dosages showed similar increases in QT time under conscious conditions, differences in repolarization parameters were seen under anesthesia, which could have proarrhythmic consequences. Indeed, subgroup analysis confirmed that LV MAPD values >500 ms in the dronedarone group were consistently associated with ectopic beats and TdP. Point 3, the different electrophysiological and arrhythmic outcomes of the drugs in the present study could suggest that chronic amiodarone exerts its beneficial effect by (1) modulating the ion channels differently, (2) inhibiting thyroid hormone activation in cardiac muscle, or (3) a combination of the two.^5,22

Clinical Implications
The CHF-STAT, CAMIAT, and EMIAT trials showed that amiodarone lacked proarrhythmia and reduced the incidence of arrhythmias and arrhythmic death in high-risk patients.^1,3,4 The present study demonstrates that the preventive effect of amiodarone on EAD formation and/or ventricular ectopic activity could account for the clinical safety and efficacy of the drug. The possible proarrhythmic effects of dronedarone should be carefully evaluated in future clinical trials.

Limitations
The selection of only 1 dosage in relatively small groups and possible predisposing factors prevent us from drawing definite conclusions about the proarrhythmic outcome of dronedarone.

Conclusions
Amiodarone is the first drug having pronounced class III effects, which do not result in TdP in this model. This is in agreement with the clinical safety of the drug and supports the validity of the model for screening arrhythmic potential of (anti-arrhythmic) drugs. The absence of TdP with amiodarone can be explained by (1) the absence of EADs and/or ventricular ectopic activity in all animals and (2) a homogeneous increase in LV and RV MAPD in the majority of dogs.

	Acknowledgments

 
Financial support by the Netherlands Heart Foundation (98.042), the Netherlands Society for Scientific Research (902-16-214), and Sanofi-Synthélabo, Paris, France, is gratefully acknowledged. The authors would like to thank Dr Paul Volders for critical reading of the manuscript. The helpful discussions with Drs Dino Nisato and Patrick Gautier, Sanofi-Synthélabo, Montpellier, France, are greatly appreciated.

	Footnotes

 
Guest Editor for this article was Hassan Garan, MD, New York Presbyterian Medical Center, New York, NY.

Received April 20, 2001; revision received September 13, 2001; accepted September 14, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med.. 1995; 333: 77–82.[Abstract/Free Full Text]

2. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol.. 1995; 6: 920–936.[Medline] [Order article via Infotrieve]

3. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet.. 1997; 349: 675–682.[Medline] [Order article via Infotrieve]

4. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators. Lancet.. 1997; 349: 667–674.[Medline] [Order article via Infotrieve]

5. Singh BN, Venkatesh N, Nademanee K, et al. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis.. 1989; 31: 249–280.[Medline] [Order article via Infotrieve]

6. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol.. 1997; 30: 791–798.[Abstract]

7. Manning A, Thisse V, Hodeige D, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol.. 1995; 25: 252–261.[Medline] [Order article via Infotrieve]

8. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation.. 1999; 100: 2276–2281.[Abstract/Free Full Text]

9. Djandjighian L, Planchenault J, Finance O, et al. Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. J Cardiovasc Pharmacol.. 2000; 36: 376–383.[Medline] [Order article via Infotrieve]

10. Verduyn SC, Vos MA, van der Zande J, et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol.. 1997; 30: 1575–1584.[Abstract]

11. Vos MA, de Groot SH, Verduyn SC, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation.. 1998; 98: 1125–1135.[Abstract/Free Full Text]

12. Verduyn SC, Vos MA, Leunissen HD, et al. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol.. 1999; 33: 212–222.[Medline] [Order article via Infotrieve]

13. Vos MA, Verduyn SC, Wellens HJJ. Early afterdepolarizations in the in situ canine heart: mechanistic insights into acquired torsade de pointes arrhythmias.In: Franz, MR ed. Monophasic Action Potentials: Bridging Cell and Bedside. Armonk, NY: Futura Publishing; 2000: 553–569.

14. Verduyn SC, Ramakers C, Snoep G, et al. Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling. Am J Physiol.. 2001; 280: H2882–H2890.[Abstract/Free Full Text]

15. Van Opstal JM, Leunissen JD, Wellens HJ, et al. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of torsade de pointes arrhythmias. Eur J Pharmacol.. 2001; 412: 67–76.[Medline] [Order article via Infotrieve]

16. Van Opstal JM, Verduyn SC, Leunissen HD, et al. Electrophysiological parameters indicative of sudden cardiac death in the dog with chronic complete AV-block. Cardiovasc Res.. 2001; 50: 354–361.[Abstract/Free Full Text]

17. Sicouri S, Moro S, Litovsky S, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol.. 1997; 8: 1269–1279.[Medline] [Order article via Infotrieve]

18. Van de Water A, Verheyen J, Xhonneux R, et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods.. 1989; 22: 207–217.[Medline] [Order article via Infotrieve]

19. Latini R, Connolly SJ, Kates RE. Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther.. 1983; 224: 603–608.[Abstract/Free Full Text]

20. Merot J, Charpentier F, Poirier JM, et al. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. Cardiovasc Res.. 1999; 44: 303–314.[Abstract/Free Full Text]

21. Mitchell LB, Wyse DG, Gillis AM, et al. Electropharmacology of amiodarone therapy initiation: time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation.. 1989; 80: 34–42.[Abstract/Free Full Text]

22. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res.. 1997; 35: 13–29.[Free Full Text]

23. Mattioni TA, Zheutlin TA, Sarmiento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes: long-term safety and efficacy. Ann Intern Med.. 1989; 111: 574–580.

24. Sager PT, Uppal P, Follmer C, et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation.. 1993; 88: 1063–1071.[Abstract/Free Full Text]

25. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol.. 1989; 14: 172–184.[Abstract]

26. Volders PGA, Vos MA, Szabo B, et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res.. 2000; 46: 376–392.[Free Full Text]

27. Vos MA, Gorenek B, Verduyn SC, et al. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Cardiovasc Res.. 2000; 48: 421–429.[Abstract/Free Full Text]

28. Laurita KR, Girouard SD, Akar FG, et al. Modulated dispersion explains changes in arrhythmia vulnerability during premature stimulation of the heart. Circulation.. 1998; 98: 2774–2780.[Abstract/Free Full Text]

29. El-Sherif N, Turitto G. The long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol.. 1999; 22: 91–110.[Medline] [Order article via Infotrieve]

30. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol.. 1998; 32: 1063–1067.[Abstract/Free Full Text]

31. Ohta M, Karagueuzian HS, Mandel WJ, et al. Acute and chronic effects of amiodarone on delayed afterdepolarization and triggered automaticity in rabbit ventricular myocardium. Am Heart J.. 1987; 113: 289–296.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				C. Graff, J. Matz, E. B. Christensen, M. P. Andersen, J. K. Kanters, E. Toft, S. Pehrson, T. B. Hardahl, J. Nielsen, and J. J. Struijk Quantitative Analysis of T-wave Morphology Increases Confidence in Drug-Induced Cardiac Repolarization Abnormalities: Evidence From the Investigational IKr Inhibitor Lu 35-138 J. Clin. Pharmacol., November 1, 2009; 49(11): 1331 - 1342. [Abstract] [Full Text] [PDF]

				C. Patel, G.-X. Yan, and P. R. Kowey Dronedarone Circulation, August 18, 2009; 120(7): 636 - 644. [Abstract] [Full Text] [PDF]

				L. Wu, S. Rajamani, J. C. Shryock, H. Li, J. Ruskin, C. Antzelevitch, and L. Belardinelli Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone Cardiovasc Res, February 1, 2008; 77(3): 481 - 488. [Abstract] [Full Text] [PDF]

				M. Hinterseer, M. B. Thomsen, B.-M. Beckmann, A. Pfeufer, R. Schimpf, H.-E. Wichmann, G. Steinbeck, M. A. Vos, and S. Kaab Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study Eur. Heart J., January 2, 2008; 29(2): 185 - 190. [Abstract] [Full Text] [PDF]

				S. Moro, M. Ferreiro, D. Celestino, E. Medei, M. V. Elizari, and S. Sicouri In Vitro Effects of Acute Amiodarone and Dronedarone on Epicardial, Endocardial, and M Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2007; 12(4): 314 - 321. [Abstract] [PDF]

				C. Antzelevitch Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2024 - H2038. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes Europace, September 1, 2007; 9(suppl_4): iv4 - iv15. [Abstract] [Full Text] [PDF]

				K. Ahmad and P. Dorian Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace, September 1, 2007; 9(suppl_4): iv16 - iv22. [Abstract] [Full Text] [PDF]

				E. Shantsila, T. Watson, and G. Y. Lip Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias Europace, September 1, 2007; 9(suppl_4): iv37 - iv44. [Abstract] [Full Text] [PDF]

				K. M Dale and C M. White Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter Ann. Pharmacother., April 1, 2007; 41(4): 599 - 605. [Abstract] [Full Text] [PDF]

				M. J. Tafreshi and J. Rowles A Review of the Investigational Antiarrhythmic Agent Dronedarone Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 15 - 26. [Abstract] [PDF]

				M. B. Thomsen, P. G.A. Volders, J. D.M. Beekman, J. Matz, and M. A. Vos Beat-to-Beat Variability of Repolarization Determines Proarrhythmic Outcome in Dogs Susceptible to Drug-Induced Torsades de Pointes J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1268 - 1276. [Abstract] [Full Text] [PDF]

				A. Kijtawornrat, Y. Nishijima, B. M. Roche, B. W. Keene, and R. L. Hamlin Use of a Failing Rabbit Heart as a Model to Predict Torsadogenicity Toxicol. Sci., September 1, 2006; 93(1): 205 - 212. [Abstract] [Full Text] [PDF]

				T. W. Heinrich, L. A. Biblo, and J. Schneider Torsades de Pointes Associated With Ziprasidone Psychosomatics, June 1, 2006; 47(3): 264 - 268. [Full Text] [PDF]

				M. B. Thomsen, S. C. Verduyn, M. Stengl, J. D.M. Beekman, G. de Pater, J. van Opstal, P. G.A. Volders, and M. A. Vos Increased Short-Term Variability of Repolarization Predicts d-Sotalol-Induced Torsades de Pointes in Dogs Circulation, October 19, 2004; 110(16): 2453 - 2459. [Abstract] [Full Text] [PDF]

				C. Antzelevitch, L. Belardinelli, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, and G. Thomas Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties Circulation, August 24, 2004; 110(8): 904 - 910. [Abstract] [Full Text] [PDF]

				L. Wu, J. C. Shryock, Y. Song, Y. Li, C. Antzelevitch, and L. Belardinelli Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 599 - 605. [Abstract] [Full Text] [PDF]

				M. Peschar, K. Vernooy, R. N Cornelussen, X. A.A.M Verbeek, R. S Reneman, M. A Vos, and F. W Prinzen Structural, electrical and mechanical remodeling of the canine heart in AV-block and LBBB Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D61 - D65. [Abstract] [Full Text] [PDF]

				C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83. [Abstract] [PDF]

				B. N. Singh and N. Wadhani Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S85 - S97. [Abstract] [PDF]

				M. B. Thomsen, P. G. A. Volders, M. Stengl, R. L. H. M. G. Spaatjens, J. D. M. Beekman, U. Bischoff, M. A. Kall, K. Frederiksen, J. Matz, and M. A. Vos Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 776 - 784. [Abstract] [Full Text] [PDF]

				J. M. Di Diego, L. Belardinelli, and C. Antzelevitch Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation Circulation, August 26, 2003; 108(8): 1027 - 1033. [Abstract] [Full Text] [PDF]

				H. C. van Beeren, W. M. C. Jong, E. Kaptein, T. J. Visser, O. Bakker, and W. M. Wiersinga Dronerarone Acts as a Selective Inhibitor of 3,5,3'-Triiodothyronine Binding to Thyroid Hormone Receptor-{alpha}1: In Vitro and in Vivo Evidence Endocrinology, February 1, 2003; 144(2): 552 - 558. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Sympathetic modulation of the long QT syndrome Eur. Heart J., August 2, 2002; 23(16): 1246 - 1252. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Opstal, J. M. Articles by Vos, M. A. Search for Related Content PubMed PubMed Citation Articles by van Opstal, J. M. Articles by Vos, M. A. Related Collections Electrophysiology Cardiovascular Pharmacology Animal models of human disease Arrythmias-basic studies Arrhythmias, clinical electrophysiology, drugs